CN1051713C - Umbellate pore fungus and poria cocos antidiarrhea oral liquid and its production technology - Google Patents
Umbellate pore fungus and poria cocos antidiarrhea oral liquid and its production technology Download PDFInfo
- Publication number
- CN1051713C CN1051713C CN95117485A CN95117485A CN1051713C CN 1051713 C CN1051713 C CN 1051713C CN 95117485 A CN95117485 A CN 95117485A CN 95117485 A CN95117485 A CN 95117485A CN 1051713 C CN1051713 C CN 1051713C
- Authority
- CN
- China
- Prior art keywords
- gram
- rhizoma
- atractylodis macrocephalae
- radix
- radix scutellariae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Abstract
The present invention discloses a traditional Chinese medicine for treating diarrhea, which is prepared from white atractylodes rhizome, tuckahoe, polyporus, pinellin tuber, tangerine peel, cassia, scutellaria root, cyrtomium rhizome and garden burnet which are used as active components, and the medicine has good effect on infant rotavirus enteritis.
Description
The present invention is a kind of diarrheal Chinese medicine that is used for the treatment of, and mainly is the Chinese patent medicine that is used for the treatment of infantile rotavirus enteritis.The invention also discloses the said Chinese patent medicine production technology that is used for the treatment of infantile rotavirus enteritis.
Infantile rotavirus enteritis is mainly due to the rotavirus, shows as the time in autumn to occur having loose bowels, and stool moisture content is heavy, color is light, and has symptom light, moderate dehydration short urination.Still there is not specific short for infantile rotavirus enteritis.WHO recommends the ORS therapy, and Chinese medicine rotavirus diarrhoea has good efficacy, and existing " GEGEN QINLIAN DIWAN " appearance, and curative effect is rather good.But this ball is only applicable to belong to the diarrhoea of hygropyretic dysentery type, and rotavirus diarrhoea belongs to " watery diarrhea " at about 2/3 infant of China, still lacks active drug targetedly at present for the diarrhoea of this type.
The object of the invention then is to develop a kind of effective medicine at " watery diarrhea type " infantile rotavirus enteritis.
Another object of the present invention has provided the production technology of the Chinese medicine of treatment infantile rotavirus enteritis.
The prescription composition of the said medicine of this paper is counted as follows by weight ratio:
Rhizoma Atractylodis Macrocephalae 200-350 part Poria 200-350 part Polyporus 300-400 part
Rhizoma Pinelliae 200-300 part Pericarpium Citri Reticulatae 200-350 part Cortex Cinnamomi 100-250 part
Radix Scutellariae 200-350 part Rhizoma Osmundae 300-400 part Radix Sanguisorbae 500-600 part
The each component preferred amount ranges of above-mentioned prescription is:
Rhizoma Atractylodis Macrocephalae 200-270 part Poria 200-250 part Polyporus 300-350 part
Rhizoma Pinelliae 200-250 part Pericarpium Citri Reticulatae 200-250 part Cortex Cinnamomi 100-170 part
Radix Scutellariae 250-300 part Rhizoma Osmundae 300-350 part Radix Sanguisorbae 500-550 part
The preferred Rhizoma Atractylodis Macrocephalae (parched with bran) of the said Rhizoma Atractylodis Macrocephalae in the prescription of medicine of the present invention, the method for Rhizoma Atractylodis Macrocephalae (parched with bran) is: Testa Tritici is sprinkled in the heat pot, adds Rhizoma Atractylodis Macrocephalae sheet when waiting to smoke clogging, fry to coke yellow, during effusion burnt odor gas, take out, sift out Testa Tritici (every 100kg Rhizoma Atractylodis Macrocephalae sheet Testa Tritici 10kg).
The said Rhizoma Pinelliae is Rhizoma Pinelliae Preparatum preferably.
Said Radix Scutellariae is Radix Scutellariae(processed with wine) preferably, and the method for Radix Scutellariae(processed with wine) is: get scutellaria tablet, mix thoroughly with wine, run through, put in the pot, when frying to yellow skin with slow fire, take out, cool.(every 100kg scutellaria tablet is used yellow wine 10kg).
Said Radix Sanguisorbae is charred Radix Sanguisorbae preferably, and the concocting method of charred Radix Sanguisorbae is: get the Radix Sanguisorbae sheet, put in the heat pot, fry with high heat to surface black, during inner sepia, spray water a little, fry and do, take out.
The raw medicinal material of above-mentioned prescription behind the compatibility, can be prepared into various medicaments commonly used clinically according to the ordinary skill in the art in proportion, as oral liquid, and tablet, capsule, electuary, pill, injection, syrup etc.
The oral liquid formulation production technology of medicine of the present invention is as follows:
Get Poria, Polyporus and add water temperature and soak secondary (3 hours for the first time, 2 hours for the second time), add water is 10 times of amounts of crude drug at every turn, merges warm macerating liquid, filters, and filtrate is concentrated into relative density 1.02-1.03 (50 ℃), and is standby; Other gets the Rhizoma Atractylodis Macrocephalae, Pericarpium Citri Reticulatae, Cortex Cinnamomi and adds 8 times of amounts of water, extracts volatile oil with the way of distillation, and extraction time is more than 5 hours, no longer increases until the volatilization oil mass.Medicinal residues after the distillation add 4 times in water, decoct half an hour, and decocting liquid device is in addition collected; All the other four flavors decoct three times, wherein Radix Scutellariae boils the back down, add 8 times in water at every turn, decocted 1 hour at every turn, the decocting liquid after collecting decoction and the distillation, filter, filtrate is concentrated into relative density 1.16-1.19 (80 ℃), puts coldly, and adding ethanol is 60-75% to containing determining alcohol, standing over night, filter, decompression filtrate recycling ethanol adds above-mentioned warm macerating liquid to there not being the alcohol flavor, volatile oil and tween 80 (content 1-1.2%), the accent pH value is 5.0-6.5, adds water to required dose (when unit of weight is for gram in the prescription, adding water to 1000ml), leave standstill, filtration, fill, sterilization, promptly get product.
Umbellate pore fungus and poria cocos antidiarrhea oral liquid of the present invention is based on through proved recipe, the liquid oral medicine that is prepared into according to the preparation process of science.Have reliable medical effect clinically,, carried out a series of animal experiments and clinical experiment for verifying medical effect of the present invention.
One, the experimental animal models diarrheal is influenced
1. to white mice diarrheal influence due to the endotoxin
80 of Kunming kind one-level white mice are divided 6 groups, every group of male and female half and half.Gavage umbellate pore fungus and poria cocos antidiarrhea oral liquid respectively or gavage GEGEN QINLIAN DIWAN, consubstantiality hydrops, subcutaneous injection dexamethasone once a day, gavage 3 days continuously.Detailed being shown in Table 1, the last administration is the quiet notes colibacillus of every Mus endotoxin 10mg/kg after 30 minutes, then white mice is put into the glass jar that is lined with the filter paper of accurately weighing, mice of each glass cylinder, it is little of the Mus number of elements that the observation mice occurs occurring diarrhoea in diarrhoea time and 1 hour, immediately the filter paper that is lined with in the glass cylinder is taken out during end and launch, no loose stool has 1-2 loose stool as 1 grade as 0 grade on the scraps of paper; 3-4 loose stool is as 2 grades; 5-6 loose stool is as 3 grades; 6 above loose stool are as 4 grades, and keep the score through the evaluation deciding grade and level.Net weight (experiment finish paper to weigh an experiment before paper heavy) is applied manure to the fields as the serious situation index of suffering from diarrhoea in the torsion balance scraps of paper of accurately weighing in the filter paper back of drying in the shade naturally.
Table 1 umbellate pore fungus and poria cocos antidiarrhea oral liquid is to white mice diarrheal influence due to the endotoxin
The dosage Mus number diarrhoea situation (group of X ± SD)
(g/Kg.d) (only) diarrhea mice degree incubation period excrement is heavy
Percentage (%) (dividing) (level) (gram) contrast consubstantiality ponding 20 100 34.6 ± 7.62 3.9 ± 0.74 0.084 ± 0.033 umbellate pore fungus and poria cocos antidiarrhea oral liquids 30 * two a kind of reed mentioned in ancient books antidiarrhea oral liquids 10 of 3 20 50**, 47.3 ± 14.60*, 1.6 ± 1.90**, 0.010 ± 0.021 umbellate pore fungus and poria cocos antidiarrhea oral liquid 15 * 3 10 80 43.1 ± 9.58* 2.9 ± 1.73 0.032 ± 0.035** * 3 10 90 39.8 ± 11.52 3.1 ± 1.37 0.095 ± 0.052 GEGEN QINLIAN DIWAN 6.7 * 3 10 60 52.0 ± 10.30*** 2.8 ± 2.57 0.097 ± 0.100 dexamethasone 4mg/kg (sc), 10 10***, 59.0 ± 3.16***, 0.1 ± 0.32***, 0.001 ± 0.033***
* P＜0.05 * * P＜0.01 * * * P＜0.001 compared with the control
As seen from Table 1, umbellate pore fungus and poria cocos antidiarrhea oral liquid can highly significant when 30g/kg prevents white mice diarrhoea due to the endotoxin, obviously reduce diarrhoea percentage rate takes place, obviously postpone the diarrhoea latent time, and the serious range degree of obviously minimizing diarrhoea, with the 6.7g/kg GEGEN QINLIAN DIWAN of 30g/kg umbellate pore fungus and poria cocos antidiarrhea oral liquid equivalence positive effect is arranged also, but only can postpone the time that its diarrhoea occurs.
2. umbellate pore fungus and poria cocos antidiarrhea oral liquid is to prostaglandin E
2Due to white mice diarrheal influence.
50 of Kunming kind one-level white mice are divided equally 5 groups, and 10 every group, male and female half and half.Gavage consubstantiality hydrops, umbellate pore fungus and poria cocos antidiarrhea oral liquid 10g/kg, 20g/kg, 30g/kg and GEGEN QINLIAN DIWAN 6.7g/kg respectively.Pressed 1.2mg/kg in mouse subcutaneous injection PGE in 50 minutes after the administration
2, the same method is observed after the administration diarrhoea Mus number in 25 minutes, the diarrhoea time occurred in packing paper glass cylinder.The results are shown in Table 2.
Table 2 umbellate pore fungus and poria cocos antidiarrhea oral liquid is to PGE
2Due to white mice diarrheal influence
The dosage Mus number diarrhoea situation (group of X ± SD)
(g/Kg) diarrhoea mouse number (only) incubation period (branch) contrast consubstantiality ponding 10 10 12.1 ± 3.94 umbellate pore fungus and poria cocos antidiarrhea oral liquids 10 10 10 13.5 ± 4.62 umbellate pore fungus and poria cocos antidiarrhea oral liquids 20 10 5* 21.6 ± 13.1* umbellate pore fungus and poria cocos antidiarrhea oral liquid 30 10 9 18.4 ± 11.3 GEGEN QINLIAN DIWANs 6.7 10 6 22.4 ± 15.2* in (only) 25 '
* P＜0.05 compared with the control
The umbellate pore fungus and poria cocos antidiarrhea oral liquid of the visible 20g/kg of table 2 can obviously reduce diarrhoea Mus number, obviously prolongs the incubation period of suffering from diarrhoea, to prostaglandin E
2Cause that diarrhea of mouse has anti-diarrhea effect.GEGEN QINLIAN DIWAN also has similar effect.
Two, antivirus action:
Material and method:
(1), the object of observation:
It all is the infant of being in hospital of this disease epidemic period, adopt the unified diagnostic criteria in the Chinese diarrhoeal diseases diagnoses and treatment scheme, age is below 3 years old, the course of disease 5 days with interior acute diarrhea sufferer youngster, stool all is rare water sample or watery stool (sticking freeze or bloody purulent stool as the object of observation) and is divided into treatment group and observation group at random.
1, a umbellate pore fungus and poria cocos antidiarrhea oral liquid treatment group is organized in treatment: below 1 years old, and 2.5ml/ time; 1～3 year old, 5ml/ time, three times on the one, it was oral to heat.
2, matched group one dioctahedral smectite treatment group: below 1 years old, 1/3 bag/time; 1～3 year old, 1/2 bag/time, three times on the one are oral.
Two groups of administration times 3～5 days, all in two groups of treatments have a dehydrator, fluid-supplement therapy simultaneously, but all do not use antibacterials and other diarrhea.
Two, observational technique:
1, specimen collection: two groups of infants are collected the fresh excreta specimen and are done routine inspection and rotavirus nucleic acid detection all in being in hospital at that time before the treatment.Collect stool sample and do the rotavirus nucleic acid detection every day after the treatment, until leaving hospital.
2, rotavirus nucleic acid detects: detect rotavirus RNA in the stool sample with polyacrylamide gel electrophoresis (hereinafter to be referred as PAGE).With containing Ca
2Tris-HCl is diluted to 10% suspension with stool sample.With detecting viral RNA after the phenol-chloroform extracting, with 10% polyacrylamide glue gel vertical electrophoresis, the gel size is 150 * 150cm, 25～30mA, and electrophoresis 4 hours is used cma staining, the equal film recording of experimental result.
(3), curative effect judgment criteria:
Produce effects: to take medicine 24～48 hours, times of defecation is reduced to＜and 2 times/day, or return to normal number of times, the stool character recovers normal, the clinical symptoms complete obiteration.
Effectively: to take medicine 48～72 hours, times of defecation just is reduced to＜and 2 times/day, the stool character takes a turn for the better, and moisture obviously reduces, and clinical symptoms obviously disappears.
Invalid: took medicine 72 hours, diarrhoea number of times still＞2 time/day, or symptom do not have and be clearly better, even the state of an illness increases the weight of, and change the medicine person, all invalid.
Clinical data:
(1), physical data: totally 60 examples, male 36 examples, women 24 examples, minimum 32 days of age, maximum 2 years old 7 months.Treatment group (umbellate pore fungus and poria cocos antidiarrhea oral liquid group) sees Table 3, two groups of age no significant differences with matched group (smecta group) age distribution.
Table 3 age distribution group (example) age＜June～added up to treatment to organize 5 13 11 1 30 matched groups 79 12 2 30 in 1 years old～2 years old～3 years old
(2), clinical manifestation:
1, diarrhoea: (table 4)
Table 4 diarrhoea number of times
Amount to treatment group (example) 4 10 16 30 matched groups (example) 9 14 7 30 for＜5 times/day 6～10 times/day＞10 times/day and add up to 13 24 23 60
Two groups of diarrhoea feces character are watery stool or rare water just, do not accompany pus and blood or mucus.
2, heating, vomiting, upper respiratory tract infection symptoms and other clinical manifestations (table 5)
Sense symptom vomiting dehydration metabolic acidosis is gone up in the heating of table 5 symptom contrast symptom
In light heavily treatment organize 23 12 19 22 40 13 matched groups 22 16 21 24 109
Heating totally 45 examples account for 75%, wherein 37.5 ℃～38 ℃ 13 example, more than 38 ℃ to 39 ℃ of 23 example, more than 39 ℃ to 40 ℃ of 9 example.
Upper respiratory tract infection symptoms:, account for 46.67% as cough, pharynx totally 23 examples such as red.
Vomit 40 examples, account for 66.67%.
Exsiccosis 51 examples account for 35%.
Metabolic acidosis 22 examples account for 36.67%.
(3), lab testing:
1, surrounding hemogram: numeration of leukocyte 5.3 * 10
9/ L, neutrality 30～60%, lymph 20～70%.
2, stool routine examination: all do not have red, leukocyte, some cases have Oil globule +～++ +/HP.
The result:
(1), fever time:
Table 6 fever time relatively Zu Bie fever time＜24h～average fever time treatment of 48h～72h is organized 17 42 1.347 ± 0.647 matched group 16 60 1.272 ± 0.435
t＝0.45 p＞0.05
Two groups of average fever time no significant differences.
(2) diarrhoea dwell time:
1. from diarrhoea first day, diarrhoea dwell time treatment group average out to 5.17 ± 1.37 days, matched group is 4.83 ± 1.47 days, t=0.913, p＞0.05, two group no significant difference.
2. from medication first day, the treatment group antidiarrheal time was: 2.60 ± 0.894 days, matched group was 2.13 ± 0.899 days, t=2.01, p＞0.05, no significant difference.
(3) two groups of curative effects are relatively: 1, and the enteritis that nosetiology is diagnosed as HRV is totally 32 examples, Comparison of therapeutic:
Table 7 HRV positive case Comparison of therapeutic
Produce effects enabledisable total effective rate total effective rate
Relatively treatment group of the example routine number of the routine number of the routine number of number (%) (%) (%) (%) 7 (53.8) 4 (30.8) 2 (15.4) 11 (84.62) X
2=0.166 matched group 18 (84.2) 1 (5.20) 2 (10.6) 17 (89.47) p＞0.05
Two groups of total effective rates are respectively 84.62% and 89.47%, two group is not relatively had significant difference.(p＞0.05)
2, clinical diagnosis is that the curative effect of rotaviral enteritis relatively contrasts:
The curative effect of table 8 rotaviral enteritis relatively
Produce effects enabledisable total effective rate total effective rate
Relatively treatment group of the example routine number of the routine number of the routine number of number (%) (%) (%) (%) 14 (46.7) 11 (36.7) 5 (16.6) 25 (83.33) X
2=0.144 matched group 22 (73.3) 5 (16.7) 3 (10.0) 27 (90.00) p＞0.05
Two groups of total effective rates are respectively 83.33% and 90.00%, two group is not relatively had significant difference.
(4) observation of rotavirus toxin expelling time
Detect in the feces rotavirus RNA with index with the PAGE method as toxin expelling.Prove in 30 infants of treatment group, have before the back treatment of being admitted to hospital in the stool sample of 13 infants to measure rotavirus RNA through PAGE, 17 examples are the rotavirus feminine gender; In matched group 33 examples, have 20 examples to detect rotavirus RNA, 13 examples are negative.Two groups of patients transfer feminine gender (seeing Table 9) respectively at rotavirus RNA testing result in second day to the 7th day excrement example specimen to by the positive after Drug therapy.Other has some patients, until leaving hospital the same day, still can detect to viral RNA in the stool sample, proves that patient continues toxin expelling.The time that above-mentioned two groups of patients stop toxin expelling is respectively 4.4 ± 1.2 days (treatment group) and 4.8 ± 1.5 days (matched group), learns by statistics and handles t=0.63, p＞0.50, there was no significant difference.
The comparison of cloudy commentaries on classics time of rotavirus in table 9 stool sample
Treatment group control group mark this shop the moon turns to fate remarks mark this shop the moon and turns to fate remarks CR4 5 ± CR5 4+* CR13 5-CR7 3+* CR15 3+* CR11 7 ± CR19 2-CR14 4+* CR21 5-CR16 3-CR27 3+* CR20 5-CR29 5-CR24 4-CR30 5-CR25 4-CR36 3-CR26 3-CR39 4+* CR28 6+* CR42 4-CR31 6+* CR55 5+* CR38 7-CR56 6-CR43 7+*
CR47 6 -
CR48 2 +*
CR52 5 ±
CR54 4 -
CR58 2 +
CR62 2 +
▲ listed mark this shop is the natural pond treat before in the stool sample rotavirus nucleic acid detect positive
+ expression PAGE method detects viral nucleic acid in the feces
-expression PAGE method is failed detected viral nucleic acid
* represent to continue to follow the trail of conclusion again because of the patient leaves hospital
1, through clinical observation, Chinese medicine umbellate pore fungus and poria cocos antidiarrhea oral liquid treatment rotavirus enteritis compares with the dioctahedral smectite of generally acknowledging at present, for the there was no significant difference that influences of the fever time of infant, the dwell time of suffering from diarrhoea.
2, through detecting with the PAGE method, with the rotavirus toxin expelling time in the two tuckahoe oral liquids treatment of the Chinese medicine infantile diarrhea infant feces be 2 to 6 days, be 9-21 days weak points than the common toxin expelling time of reporting in the document, and compare its difference not statistically significant with smecta group.
Embodiment
Prescription:
The Rhizoma Atractylodis Macrocephalae (parched with bran) 268 gram Poria 234.5 gram Polyporus 301.5 grams
Rhizoma Pinelliae Preparatum 201 gram Pericarpium Citri Reticulataes 234.5 gram Cortex Cinnamomis 167.5 grams
Radix Scutellariae (wine is processed) 268 gram Rhizoma Osmundae 335 gram charred Radix Sanguisorbae 502.5 grams
Get Poria, Polyporus adds water temperature and soaks secondary, is respectively 3 hours and 2 hours, adds 10 times of amounts of water at every turn, merges warm macerating liquid, filters, filtrate is concentrated into relative density 1.02-1.03 (50 ℃), and is standby; Other gets the Rhizoma Atractylodis Macrocephalae, Pericarpium Citri Reticulatae, Cortex Cinnamomi and extracted volatile oil 6 hours with the way of distillation, no longer increases (more than 3.2 milliliters) until volatile oil, and the medicinal residues after the distillation add 4 times in water, decocts half an hour, and decocting liquid device is in addition collected; All the other four flavors (Radix Scutellariae boils the back down) decoct three times, add 8 times in water at every turn, decoct the decocting liquid after collecting decoction and the distillation 1 hour at every turn, filter, filtrate is concentrated into relative density 1.16-1.19 (80 ℃), puts coldly, and adding ethanol is 60% to containing determining alcohol, standing over night filters, and decompression filtrate recycling ethanol adds above-mentioned warm macerating liquid to there not being the alcohol flavor, volatile oil and 12ml tween 80, mixing, accent PH is 5.5-6.0, add water to 1000 milliliters, leave standstill, filter, fill, sterilization, promptly.
Claims (10)
1. antidiarrheal pharmaceutical composition is characterized in that it is the medicament of making by weight ratio with following raw material medicaments:
Rhizoma Atractylodis Macrocephalae 200-350 part Poria 200-350 part Polyporus 300-400 part
Rhizoma Pinelliae 200-300 part Pericarpium Citri Reticulatae 200-350 part Cortex Cinnamomi 100-250 part
Radix Scutellariae 200-350 part Rhizoma Osmundae 300-400 part Radix Sanguisorbae 500-600 part
2. pharmaceutical composition according to claim 1 is characterized in that the weight proportion of each crude drug is:
Rhizoma Atractylodis Macrocephalae 200-270 part Poria 200-250 part Polyporus 300-350 part
Rhizoma Pinelliae 200-250 part Pericarpium Citri Reticulatae 200-250 part Cortex Cinnamomi 100-170 part
Radix Scutellariae 250-300 part Rhizoma Osmundae 300-350 part Radix Sanguisorbae 500-550 part
3. pharmaceutical composition according to claim 1 is characterized in that the weight proportion of each crude drug is:
The Rhizoma Atractylodis Macrocephalae 268 gram Poria 234.5 gram Polyporus 301.5 grams
The Rhizoma Pinelliae 201 gram Pericarpium Citri Reticulataes 234.5 gram Cortex Cinnamomis 167.5 grams
Radix Scutellariae 268 gram Rhizoma Osmundae 335 gram Radix Sanguisorbaes 502.5 grams
4. according to claim 1,2 or 3 pharmaceutical composition, it is characterized in that having added solubilizing agent.
5. pharmaceutical composition according to claim 4 is characterized in that said solubilizing agent is a tween 80, and its content is 1-1.2%.
6. according to claim 1,2 or 3 pharmaceutical composition, it is characterized in that the said Rhizoma Atractylodis Macrocephalae is a Rhizoma Atractylodis Macrocephalae (parched with bran), the Rhizoma Pinelliae is a Rhizoma Pinelliae Preparatum, and Radix Scutellariae is that wine is processed Radix Scutellariae, and Radix Sanguisorbae is a charred Radix Sanguisorbae.
7. according to claim 1,2 or 3 pharmaceutical composition, it is characterized in that said medicament is a kind of in oral liquid, tablet, capsule, electuary, pill, injection, the syrup.
8. the production method of a umbellate pore fungus and poria cocos antidiarrhea oral liquid is characterized in that raw materials usedly being:
The Rhizoma Atractylodis Macrocephalae 268 gram Poria 234.5 gram Polyporus 301.5 grams
The Rhizoma Pinelliae 201 gram Pericarpium Citri Reticulataes 234.5 gram Cortex Cinnamomis 167.5 grams
Radix Scutellariae 268 gram Rhizoma Osmundae 335 gram Radix Sanguisorbaes 502.5 grams
Tween 80 10-12 milliliter
Production technology is:
Get Poria, Polyporus adds water temperature and soaks twice, is respectively 3 hours and 2 hours, add water is 10 times of amounts of crude drug at every turn, merges warm macerating liquid, filters, filtrate is concentrated into 50 ℃ of relative density 1.02-1.03, and is standby; Other gets the Rhizoma Atractylodis Macrocephalae, Pericarpium Citri Reticulatae, Cortex Cinnamomi and adds 8 times of amounts of water, extracts volatile oil with the way of distillation, and extraction time no longer increased until the volatilization oil mass more than 5 hours, and the medicinal residues after the distillation add 4 times in water, decoct half an hour, and other device of boiling medicine is collected; All the other 4 flavors are fried in shallow oil three times, and wherein Radix Scutellariae boils the back down, adds 8 times in water at every turn, the each decoction 1 hour, the decocting liquid after collecting decoction and the distillation filters, filtrate is concentrated into 80 ℃ of relative density 1.16-1.19, puts coldly, and adding ethanol is 60-75% to containing determining alcohol, standing over night filters, and decompression filtrate recycling ethanol is to there not being the alcohol flavor, add above-mentioned warm macerating liquid, volatile oil and tween 80, adjust pH are that 5.0-6.5 adds water to 1000 milliliters, leave standstill, filter, fill, sterilization are promptly.
9. production method according to Claim 8 is characterized in that the said Rhizoma Atractylodis Macrocephalae is a Rhizoma Atractylodis Macrocephalae (parched with bran), and the Rhizoma Pinelliae is a Rhizoma Pinelliae Preparatum, and Radix Scutellariae is a Radix Scutellariae(processed with wine), Radix Sanguisorbae ground charred Radix Sanguisorbae.
10. production method according to Claim 8 is characterized in that collecting decoction concentrates the back and adds ethanol to containing determining alcohol 60%; Adjust pH is 5.5-6.0 behind adding volatile oil and the tween 80.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN95117485A CN1051713C (en) | 1995-11-22 | 1995-11-22 | Umbellate pore fungus and poria cocos antidiarrhea oral liquid and its production technology |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN95117485A CN1051713C (en) | 1995-11-22 | 1995-11-22 | Umbellate pore fungus and poria cocos antidiarrhea oral liquid and its production technology |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1150906A CN1150906A (en) | 1997-06-04 |
| CN1051713C true CN1051713C (en) | 2000-04-26 |
Family
ID=5081272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN95117485A Expired - Lifetime CN1051713C (en) | 1995-11-22 | 1995-11-22 | Umbellate pore fungus and poria cocos antidiarrhea oral liquid and its production technology |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1051713C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101152307B (en) * | 2006-09-30 | 2012-02-22 | 曾雄辉 | Traditional Chinese medicine soft capsule for treating abdominal pain and lax, and method for preparing the same |
| CN102293884B (en) * | 2011-08-26 | 2013-04-17 | 太极集团重庆涪陵制药厂有限公司 | Preparation method of anti-diarrheal medicinal composition |
| CN102908481B (en) * | 2012-09-29 | 2014-05-14 | 庞维胜 | Preparation for treating autumn diarrhea and preparation method thereof |
| CN103520384A (en) * | 2013-10-17 | 2014-01-22 | 郭峰 | Traditional Chinese medicine for treating infantile autumn diarrhea through enteroclysis |
| CN116392532A (en) * | 2023-05-22 | 2023-07-07 | 太极集团重庆涪陵制药厂有限公司 | Bipolaris antidiarrheal granule volatile oil clathrate, and its preparation method and application |
-
1995
- 1995-11-22 CN CN95117485A patent/CN1051713C/en not_active Expired - Lifetime
Non-Patent Citations (3)
| Title |
|---|
| 《中医杂志》1986年第27卷第7期 1986. 7.31 孙英华等,中药散剂治疗婴幼儿腹泻569例 * |
| 《中医杂志》1986年第27卷第7期 1986. 7.31 孙英华等,中药散剂治疗婴幼儿腹泻569例;《湖北中医杂志》1991年第13卷第2期 1991. 2.28 杜克宽,中药治疗婴幼儿虚寒型腹泻100例 * |
| 《湖北中医杂志》1991年第13卷第2期 1991. 2.28 杜克宽,中药治疗婴幼儿虚寒型腹泻100例 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1150906A (en) | 1997-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101028507A (en) | Chinese-medicinal composition for treating asthma | |
| CN100346819C (en) | Chinese medicinal preparation for treating prostate disease and its production method | |
| CN1706442A (en) | Prepn process of medicine for treating icteric diseases and oral liquid containing the medicine | |
| CN1813961A (en) | Medicinal composition for treating astriction | |
| CN103301267B (en) | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof | |
| CN100493586C (en) | Oral liquid for treating breast cancer, liver cancer or lung caner, and preparation thereof | |
| CN1051713C (en) | Umbellate pore fungus and poria cocos antidiarrhea oral liquid and its production technology | |
| CN102698207A (en) | Traditional Chinese medicine composition for treating hepatopathy and preparation method thereof | |
| CN101053619A (en) | Medicine for treating pulmonary fibrosis | |
| CN1686501A (en) | Compound Chinese medicine for treating child diarrhea and its preparation method | |
| CN116139237B (en) | A Chinese medicinal composition for preventing and treating respiratory tract infection caused by coronavirus, and its application | |
| CN1262951A (en) | Medicine for curing arthralgia-syndrome resulted from wind,cold and dampness and its preparation method | |
| CN1304735A (en) | Medicine for curing chronic colitis | |
| CN1180806C (en) | Pure Chinese medicine preparation | |
| CN103041081B (en) | Medicament composition for treating spleen-insufficiency diarrhea type irritable bowel syndrome and preparation method thereof | |
| CN102266538B (en) | Traditional Chinese medicinal composition for treating damp-heat dysentery and preparation method thereof | |
| CN111671868B (en) | Novel traditional Chinese medicine composition for treating mild symptoms, namely coronavirus pneumonia and insomnia | |
| CN100457169C (en) | Medicine for treating chronic colitis and its preparing process | |
| CN1148217C (en) | Chinese medicine for treating chronic bronchitis | |
| CN1169555C (en) | Decocted pill medicine for treating excess syndrome of hepatitis B | |
| CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome | |
| CN1883582A (en) | Pharmaceutical composition for treating liver disease and method for preparing same | |
| CN1063077C (en) | Traditional Chinese medicine composition for lowering blood-lipid, and method for preparing same | |
| CN1101559A (en) | Traditional Chinese medicine oral administration liquid for anti-cancer and its preparing method | |
| CN102755598B (en) | Medicine for treating acute gouty arthritis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: TAI CHI GROUP CHONGQING FULING PHARMACEUTICAL FACT Free format text: FORMER NAME OR ADDRESS: TAIJI GROUP FULING PHARMACEUTICAL FACTORY |
|
| CP03 | Change of name, title or address |
Address after: 648000 1 Tai Chi Avenue, Fuling District, Chongqing Patentee after: Taiji Group Chongqing Fuling Pharmaceutical Factory Co., Ltd. Address before: 648000 No. 68, Jianshe Road, Sichuan, Fuling Patentee before: Taiji Group Fuling Pharmaceutical Factory |
|
| CX01 | Expiry of patent term |
Granted publication date: 20000426 |
|
| EXPY | Termination of patent right or utility model |